الفهرس 
NORMAL ENDOMETRIUMOnly 14 pages are availabe for public view
 |  | from | 222 |  |  |
| | | from | 222 | | |
Abstract
Abstract
Objective; The aim of the study is to evaluate the immunohistochemical expression of stem cell markers CD133 and Oct-4 in cases of endometrial hyperplasia and endometrial carcinoma in comparison to normal endometrium and correlate the results with the available clinicopathological data.
Study design: A retrospective study
Materials and methods; A total of 90 archived formalin fixed and paraffin specimens were obtained from 30 cases of normal endometrium, 30 cases of endometrial hyperplasia, and 30 cases of endometrial carcinomas during the period from 2010-2013.
Results; The high expression of CD133 protein was detected in 4 cases (13.3%) of normal endometrium. In endometrial hyperplasia the high expression of CD133 protein was detected in 5 cases; 2 cases,1 case and 2 cases (22.2%), (8.3%) and (22.2%) in simple endometrial hyperplasia (SHE), atypical endometrial hyperplasia (EHA) and complex endometrial hyperplasia (CEH) respectively. On the other hand, endometrial carcinoma cases showed high expression of CD133 protein in 3 cases (11.1%), diagnosed as type 1 endomterial carcinoma, while type 2 endometrial carcinoma cases showed only low expression.
While the high expression of Oct4 protein in normal endometrium was in 3 cases (10.0%). In endometrial hyperplasia the high expression of Oct4 protein was detected in 9 cases; 2 cases (22.2%), 4 cases (44.4%) and 3 cases (33.3%). In SEH, EHA and CEH respectively. As regard the expression of Oct4 protein in endometrial carcinoma cases; the highest expression was revealed in 10 cases (37%) in type 1 carcinoma while type 2 showed only low expression.
A significant relationship was observed between CD133, Oct4 and tumor stage (p=0.00).
Conclusion A positive correlation between the markers CD133 and Oct4 and tumor stage was observed, indicating that CD133 and Oct4 markers might be used as a significant prognostic tools. Further studies with larger sample size and follow up data at longer intervals are recommended.
Key words CD133, Oct4, endomterial carcinoma, endometrial hyperplasia, immunohistochemistry